SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.

Highlights Shenzhen Hepalink Pharmaceutical Group Co., Ltd.

Equities

002399

CNE100000P02

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-07-07 pm EDT			5-day change	1st Jan Change
8.33 ^CNY	-3.48%		-4.47%	-28.99%

Apr. 29	Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 02	Shenzhen Hepalink Receives Thai Approval for Blood Clot Drug Exarane	MT

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 29	CI
Thailand Food and Drug Administration Approves for Sales in the Market of Exarane Produced by Shenzhen Hepalink Pharmaceutical Group Co., Ltd.'s Wholly-Owned Subsidiary Shenzhen Techdow Medicine Co., Ltd	Apr. 02	CI
Shenzhen Hepalink Pharmaceutical Widens 2023 Loss as Revenue Drops 24%	Apr. 01	MT
Shenzhen Techdow Medicine Co., Ltd., Wholly-Owned Subsidiary of Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Announces Exarane Obtains Approval from New Zealand Medicines and Medical Devices Safety Authority	Mar. 28	CI
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Announces No Final Dividend for the Year Ended 31 December 2023	Mar. 28	CI
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
Shenzhen Hepalink Forecasts Loss in 2023; Shares Slide 4%	Jan. 31	MT
Shenzhen Hepalink Flags Provisions of Up to 950 Million Yuan; Shares Fall 4%	Jan. 31	MT
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Provides Earnings Guidance for the Period from January 1, 2023 to December 31, 2023	Jan. 30	CI
Hepalink Faces Regulatory Scrutiny After 12 Million Euro Telecom Fraud; Hong Kong Shares Down 3%	Jan. 15	MT
Hepalink Pharma Associate HighTide Therapeutics to Debut in Hong Kong on Friday	Dec. 18	MT
Hepalink Pharmaceutical's Profit Drops 86% in Q3; Shares Slump 4%	23-10-31	MT
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-30	CI
Hepalink Pharmaceutical's H1 Attributable Profit Plunges on Higher Share of Losses from Associates	23-08-31	MT
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-30	CI
Shenzhen Hepalink Pharmaceutical’s H1 Profit to Fall By Up to 81%	23-07-17	MT
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Announces Final Cash Dividend on A Shares for the Year 2022, Payable on July 18, 2023	23-07-11	CI
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Approves Cash Dividend for 2022	23-05-23	CI
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Announce Payment of Dividend on H Shares for the Year Ended December 31, 2022, Payable on May 31, 2023	23-05-22	CI
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-28	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Shenzhen Hepalink Pharmaceutical Group Co., Ltd.

Equities

002399

CNE100000P02

Highlights

Filters